Cellebrite DI ALERT: Securities Fraud Investigation by Block & Leviton Could Allow Investors to Recover Losses

Block & Leviton is investigating Cellebrite DI (NASDAQ: CLBT) for potential securities law violations. Investors who have lost money in their Cellebrite DI investment should contact the firm to learn more about how they might recover those losses. For more details, visit https://blockleviton.com/cases/clbt . Block & Leviton is investigating whether Cellebrite and certain of its executives may have violated the federal securities laws. In May 2026, Cellebrite's then-CEO told investors that its U.S. federal business was "beginning to accelerate" and pointed to a meaningful pipeline of large government deals expected to close in the second quarter. On August 13, 2026, the company reported second-quarter results that missed revenue and earnings estimates and cut its full-year annual recurring revenue guidance by roughly $15 million at the midpoint, blaming a handful of large federal and European government deals that slipped out of the quarter due to newly encountered procurement and "foreign entity permit" requirements, as well as weaker-than-expected pricing on "Insights" conversions. The company simultaneously announced an abrupt CEO change, replacing Tom Hogan with Shiv Ramji effective the same day. Cellebrite shares fell approximately 32% on the news. The investigation concerns whether the company adequately disclosed the risks to its government pipeline when it was reassuring investors earlier in the year. Anyone who purchased Cellebrite DI common stock and has seen their shares fall may be eligible, whether or not they have sold their investment. Investors should contact Block & Leviton to learn more. Block & Leviton is investigating whether the Company committed securities law violations and may file an action to attempt to recover losses on behalf of investors who have lost money. If you've lost money on your investment, you should contact Block & Leviton to learn more via our case website , by email at [email protected] , or by phone at (888) 256-2510. If you have non-public information about Cellebrite DI, you should consider assisting in our investigation or working with our attorneys to file a report with the Securities Exchange Commission under their whistleblower program. Whistleblowers who provide original information to the SEC may receive rewards of up to 30% of any successful recovery. For more information, contact Block & Leviton at [email protected] or by phone at (888) 256-2510.